Loading
Led CheckMate 069, the first randomised trial of nivolumab plus ipilimumab, and defines how to manage immunotherapy side effects.
Michael Postow led CheckMate 069, the randomised phase 2 trial that first showed nivolumab plus ipilimumab dramatically improves response rates over ipilimumab alone in melanoma and set up CheckMate 067. He wrote the widely cited NEJM review of immune-related adverse events and leads trials of adaptive dosing and treatment discontinuation. He chairs the melanoma service at MSKCC.
Shares CheckMate 067, CTLA-4, Advanced melanoma (unresectable stage III and stage IV), Ipilimumab and the tags melanoma, immunotherapy.
Shares Advanced melanoma (unresectable stage III and stage IV), Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
Shares CheckMate 067, Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
Shares CheckMate 067, CTLA-4, Advanced melanoma (unresectable stage III and stage IV), Ipilimumab.
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag immunotherapy.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tags melanoma, immunotherapy.
Shares CheckMate 067, Melanoma and the tags melanoma, immunotherapy.
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors and the tag melanoma.